Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 Hylek, 2003, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med, 349, 1019, 10.1056/NEJMoa022913 Birman-Deych, 2006, Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation, Stroke, 37, 1070, 10.1161/01.STR.0000208294.46968.a4 Hylek, 2007, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation, Circulation, 115, 2689, 10.1161/CIRCULATIONAHA.106.653048 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Once-daily edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Dentali, 2012, Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature, Circulation, 126, 2381, 10.1161/CIRCULATIONAHA.112.115410 Baker, 2012, Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation, Circ Cardiovasc Qual Outcomes, 5, 711, 10.1161/CIRCOUTCOMES.112.966572 Lip, 2012, Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation, J Am Coll Cardiol, 60, 738, 10.1016/j.jacc.2012.03.019 Dogliotti, 2013, Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin, Clin Cardiol, 36, 61, 10.1002/clc.22081 Miller, 2012, Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am J Cardiol, 110, 453, 10.1016/j.amjcard.2012.03.049 Ruff, 2010, Am Heart J, 160, 635, 10.1016/j.ahj.2010.06.042 Connolly, 2010, Newly identified events in the RE-LY trial, N Engl J Med, 363, 1875, 10.1056/NEJMc1007378 Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 Ezekowitz, 2010, Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation, Circulation, 122, 2246, 10.1161/CIRCULATIONAHA.110.973735 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Diener, 2010, Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial, Lancet Neurol, 9, 1157, 10.1016/S1474-4422(10)70274-X Mahaffey, 2013, Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial, Ann Intern Med, 158, 861, 10.7326/0003-4819-158-12-201306180-00003 Hankey, 2012, Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF, Lancet Neurol, 11, 315, 10.1016/S1474-4422(12)70042-X Wallentin, 2013, Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation, Circulation, 127, 2166, 10.1161/CIRCULATIONAHA.112.142158 Hohnloser, 2012, Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial, Eur Heart J, 33, 2821, 10.1093/eurheartj/ehs274 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Flaherty, 2007, The increasing incidence of anticoagulant-associated intracerebral hemorrhage, Neurology, 68, 116, 10.1212/01.wnl.0000250340.05202.8b Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Hughes, 2008, Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data, Thromb Haemost, 99, 295, 10.1160/TH07-08-0508 2007, Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Go, 2009, Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study, Circulation, 119, 1363, 10.1161/CIRCULATIONAHA.108.816082 Piccini, 2013, Circulation, 127, 224, 10.1161/CIRCULATIONAHA.112.107128 Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 Garcia, 2010, New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs, Thromb Haemost, 104, 1099, 10.1160/TH10-07-0491 Morgan, 2009, Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control, Thromb Res, 124, 37, 10.1016/j.thromres.2008.09.016 Gallagher, 2011, Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients, Thromb Haemost, 106, 968, 10.1160/TH11-05-0353 Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000 Cleophas, 2007, Meta-analysis, Circulation, 115, 2870, 10.1161/CIRCULATIONAHA.105.594960 Cabral, 2011, Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification, J Thromb Haemost, 9, 441, 10.1111/j.1538-7836.2010.04179.x Larsen, 2013, Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study, J Am Coll Cardiol, 61, 2264, 10.1016/j.jacc.2013.03.020